REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today ...

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

HHMI Investigator Kevan Shokat and his lab are charting new therapies to outmaneuver drug resistance and better target common cancer cell mutations.

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...

Pancreatic ductal adenocarcinoma (PDAC) has a low 5-year survival rate of 12%. Even though KRAS is mutated in about 88% of PDACs, the KRAS G12C mutation is rare, limiting the use of KRAS G12C ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...

A research team led by MSK physician-scientist Dr. Piro Lito discovered that certain inhibitors can short-circuit the out-of-control signaling caused by mutations that fuel cancer growth. Each year, ...